Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

BUY Dishman Pharma - Better traction expected from CRAMS and disinfectants: AnandRathi Institutional Research

Posted On: 2016-09-25 09:04:08

Dishman Pharma - Better traction expected from CRAMS and disinfectants; Buy with a target price of Rs 226

For a better understanding of the business and the outlook for the next 2-3 years, we met the Dishman management recently. In addition to margin improvement, which has been the case for FY16 (and expected in FY17), revenue growth would be driven by growth in its CRAMS base business, additional business on the commercialization of potential molecules and the further business in disinfectants from FY18. We introduce FY19 estimates, maintaining our Rs. 226 target and Buy rating due to 33% potential.

Phase-III molecules: In its CRAMS business, Dishman has about 13 molecules in phase-III of clinical trials. Of these, about 6-7 are in oncology. The commercialization of 2-3 molecules can be expected in 18-24 months, and would be revenue drivers in CRAMS.

More outsourcing by J&J in disinfectants: There is shift of manufacturing of ~20 products by J&J from its own base to Dishman's facility. This is expected to raise the revenue base of Rs. 100m to Rs. 1bn over next 2-3 years. This outsourcing would start from FY18.

More Eprosartan business through higher volumes: Dishman guided to more outsourcing of Eprosartan by Solvay from Dishman's facility, which would begin from FY18. This would result in ~20% yoy growth in this business for Dishman.

Introducing FY19e. Our FY19 estimates are: sales Rs. 20.5bn, PAT Rs. 3.2bn, factoring in respectively 12% and 24% yoy growth, based on more business from CRAMS and disinfectants.

Valuation. At the CMP of Rs. 175, the stock trades at 13x FY17e EPS of Rs. 13.5 and 10.8x FY18e EPS of Rs. 16.1. We maintain a Buy, with a target of Rs. 226 based on 14x FY18e earnings. Risks. Currency fluctuations and delay in approvals.

Shares of DISHMAN PHARMACEUTICALS & CHEMICALS LTD. was last trading in BSE at Rs.210.05 as compared to the previous close of Rs. 217.8. The total number of shares traded during the day was 565833 in over 8274 trades.

The stock hit an intraday high of Rs. 227.9 and intraday low of 208.2. The net turnover during the day was Rs. 123652429.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

IndusInd Bank Q2FY18 Result Update - Rating - HOLD - Arihant Capital Markets
Insurance: Select large players drive growth - Kotak
Views on Tata Consultancy Services Limited Q2FY2018 Results: Angel Broking
Metals & Mining (Attractive): 2QFY18 preview-good for all - Kotak
Energy: 2QFY18E preview—strong quarter across the board - Kotak
South Indian Bank (SIB IN) - Earnings update - PAT declined owing to exceptional provision - CSEC Research
The Pitch Report - Call Update: BBTC - ACCUMULATE - TP Rs.1613 - Kotak
Result Update: Cyient Ltd - ACCUMULATE - TP Rs.576 - Kotak
Result Update: TV18 Broadcast Ltd - BUY - TP Rs.50 - Kotak
Lakshmi Vilas Bank (LVB IN) - Earnings update - Provisions surged leading to steep fall in PAT - CSEC Research
Cement prices - on a weak footing - Kotak
Company Update: Engineers India Ltd - BUY - TP Rs.182 - Kotak
Company Update: Insecticides (India) Ltd - SELL - TP Rs.830 - Kotak
Logistics: Another blow to the e-way bill and thus to prospects of formalizing the sector - Kotak
Cement: 2QFY18 preview-healthy volumes, costs outweigh realizations - Kotak
Company Update: Time Technoplast Ltd - ACCUMULATE - TP Rs.216 - Kotak
Bumper profits ahead for Natco Pharma: Angel Broking
Banks : More questions than answers : New pricing regime likely to be introduced to replace MCLR/base rate - Kotak
Economy: RBI retains inflation focus - Kotak
BFSI : 2QFY18 preview: muted quarter for banks; stronger for NBFCs - Kotak
Telecom: LTE - 40% of data users, 80%+ of usage - Kotak
Energy - OMCs (BPCL | HPCL | IOCL): Some relief, but not enough - Kotak
Auto sales numbers for the month of September: Angel Broking
Technology: Accenture FY2018 guidance signals no change in demand trend - Kotak
Stock Picks - Maruti Suzuki, Federal Bank - Arihant Capital Market
Company Update: Gujarat Alkalies & Chemicals (GACL) - SELL - TP Rs.540 - Kotak
Stock Picks - Hero MotoCorp, Ultratech Cement - Arihant Capital Markets
Company Update: Maruti Suzuki India Limited (MSIL) - BUY - TP Rs.9061 - Kotak
Power: Monthly Tracker, September 2017 - Kotak
Consumer Products (Cautious): Observations: field trip to Patna - Kotak
Reliance Home Finance (RHFL) listed today and it is trading at 4.6x FY2017 book value: Angel Broking
Stocks Picks - TVS Motors, TCS & DCB Bank - Arihant Capital Markets Ltd
Result Update: AksharChem India Ltd - ACCUMULATE - TP Rs.800 - Kotak
Initiating Coverage: VIP Industries Ltd - BUY - TP Rs.325 - Kotak
Company Update: KNR Constructions Ltd - BUY - TP Rs.236 - Kotak
Top Stock Picks by Arihant Capital Market
Chhota (to) MOTA ideas - CALL UPDATE: Venky's India Ltd - BUY - TP Rs.2650 - Kotak
Gabriel India Limited (GABR IN) - Shift in strategy to accelerate the growth - Initiating Coverage - CSEC Research
Banks : Some signs of life; but still weak | Sanctions made in the private corporate sector undertaken by banks/FIs - Kotak
Petroleum minister's clarification on not interfering with auto fuels pricing is a relief
Energy - OMCs (BPCL | HPCL | IOCL): A false but worrying alarm - Kotak
Company Update: Mangalore Refinery and Petrochemicals Ltd (MRPL) - BUY - TP Rs.155 - Kotak
RIL scales uncharted highs - Jio Dhan Dhana Dhan: Angel Broking
Energy-Petroleum consumption: Weakness in industrial fuels; base affects auto fuels - Kotak
Company Update: GE Shipping Company (GESCO) - BUY - TP Rs.530 - Kotak
The Pitch: BSE Ltd - BUY - TP Rs.1170 - Kotak Securities
Cess hike breather for automobile companies, removes hangover on the stocks: Angel Broking
Demerger in CESC Ltd - Kotak PCG Research
Cement:Prices remain soft - Kotak
FIEM Industries Ltd - Result Update - Kotak PCG Research


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017